CD79A and COVID-19: Fifteen patients had levels of IgA at least 20% lower at day 28 than at day 0 (range 35–100%, with 5 patients having measurable levels of IgA at inclusion but not day 28), the majority of which had moderate COVID-19 (group 2), n = 9.